Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
Authors
Keywords
Tivantinib, Sorafenib, Phase I trial, VEGF inhibition, MET RTK inhibition, Advanced tumors
Journal
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 1, Pages 159-168
Publisher
Springer Nature
Online
2014-10-07
DOI
10.1007/s10637-014-0167-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
- (2013) Yasushi Soda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- c-Met inhibitors
- (2013) Anum Mughal et al. Infectious Agents and Cancer
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
- (2012) Jonathan W. Goldman et al. CANCER
- Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors
- (2012) Andrew J. Wagner et al. CANCER
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
- (2011) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- Association of activated c-Met with NRAS-mutated human melanomas
- (2011) Chandrani Chattopadhyay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of the c-Met pathway in lung cancer and the potential for targeted therapy
- (2011) Martin Sattler et al. Therapeutic Advances in Medical Oncology
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
- (2009) Xiangdong Liu et al. TRENDS IN MOLECULAR MEDICINE
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now